What Are These Two Compounds?

Ipamorelin is a pentapeptide (five amino acids) developed in the 1990s by Novo Nordisk researchers. It belongs to the growth hormone secretagogue (GHS) class and was originally catalogued in the scientific literature as NNC 26-0161. Its structure was designed to mimic ghrelin's ability to stimulate growth hormone release while minimizing effects on cortisol and prolactin, which were problems with earlier secretagogues like GHRP-6.

Mod-GRF (1-29) is a modified form of the first 29 amino acids of growth hormone-releasing hormone (GHRH). The 'Mod' prefix refers to substitutions made at four positions in the native sequence to slow enzymatic breakdown and extend the peptide's half-life in circulation. It is sometimes called CJC-1295 without DAC in vendor catalogs, though that label is technically imprecise. The parent molecule, GHRH(1-29), also known as sermorelin, has a longer clinical history, and the FDA-approved prescription drug Geref was based on sermorelin before its manufacturer withdrew it from the U.S. market for commercial reasons. Mod-GRF (1-29) itself has not received any such approval.

How Do Their Mechanisms Differ?

Ipamorelin works by binding the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. Activation of GHS-R1a in the pituitary triggers a calcium-dependent signaling cascade that prompts somatotroph cells to release stored growth hormone. Ipamorelin appears to do this without meaningfully raising ACTH, cortisol, or prolactin at the doses studied in animals, which distinguishes it from earlier GHS compounds. A 1998 paper by Raun and colleagues published in the European Journal of Endocrinology characterized this selectivity profile in rat and swine models.

Mod-GRF (1-29) works through an entirely different receptor: the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on pituitary somatotrophs. When GHRH or its analogs bind GHRHR, they activate adenylyl cyclase, raise intracellular cAMP, and stimulate both growth hormone synthesis and release. Because the two peptides act on different receptors through different second-messenger pathways, they are often described in the research literature as having complementary rather than redundant mechanisms. This mechanistic distinction is real and documented, though the clinical significance of combining them in humans has not been established in controlled trials.

One practical difference is half-life. Native GHRH(1-29) is cleaved rapidly by dipeptidyl peptidase IV (DPP-IV) and other proteases, giving it a plasma half-life measured in minutes. The amino acid substitutions in Mod-GRF (1-29) were specifically designed to resist that cleavage. Ipamorelin's small pentapeptide structure also confers relative metabolic stability compared to earlier hexapeptide secretagogues, though its half-life in humans has not been rigorously characterized in peer-reviewed literature.

What Does the Evidence Base Look Like for Each?

For ipamorelin, the foundational pharmacology work is animal-based. The 1998 Raun et al. study in the European Journal of Endocrinology (PMID 9749581) remains one of the most-cited primary sources. It demonstrated GH release in rats and pigs with the selectivity profile described above. A 1999 study by Svensson and colleagues in the same journal (PMID 10229296) examined ipamorelin's effects on bone mineral content in rats over 12 weeks, finding increases compared to controls. Both are preclinical. Ipamorelin did enter human clinical development: a Phase II trial (NCT00397956) examined it for postoperative ileus. That trial represents the most substantial human data publicly available for the compound.

For Mod-GRF (1-29) specifically, the published human evidence is thinner than for its parent compound sermorelin. Most of what researchers cite about GHRH(1-29) analogs in humans comes from sermorelin studies or from CJC-1295 with DAC, a version with a drug affinity complex that extends half-life to days. A 2006 study by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism (PMID 16822818) examined CJC-1295 with DAC in 21 healthy adults and found dose-dependent increases in GH and IGF-1 lasting several days. That compound is not the same as Mod-GRF (1-29), and extrapolating those results to the shorter-acting version requires caution.

In terms of evidence tiers, both compounds sit primarily in the preclinical category for most of the claims vendors make about them. Animal studies showing GH release are real and replicated. Human pharmacokinetic and pharmacodynamic data exist but are limited in scope and sample size. No large randomized controlled trial has evaluated either compound for body composition, recovery, or aging-related outcomes in healthy adults, which are the contexts in which they are most often marketed.

How Do Regulatory Status and Research Classification Compare?

Neither ipamorelin nor Mod-GRF (1-29) holds approval from the FDA or any equivalent regulatory agency for human therapeutic use. They are sold in the United States as research chemicals, meaning they are legal to purchase for laboratory research purposes but are not approved for human administration. This is a meaningful distinction that vendor marketing frequently blurs.

The FDA has taken action against compounding pharmacies that included ipamorelin in preparations marketed for human use. In 2023, the FDA updated its list of bulk drug substances that may not be used in compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Ipamorelin appeared on the agency's list of substances that raise significant safety concerns or lack sufficient evidence of clinical utility for compounded use. Mod-GRF (1-29) does not have the same specific regulatory history, but it similarly lacks an approved new drug application.

Sermorelin, the closest approved relative of Mod-GRF (1-29), was FDA-approved as Geref for growth hormone deficiency in children. That approval applied to sermorelin acetate as a specific pharmaceutical product, not to modified analogs sold as research chemicals. Researchers and consumers should not interpret the historical approval of sermorelin as extending to Mod-GRF (1-29).

What Distinguishes Them in the Research Context?

The clearest distinction is mechanistic. Ipamorelin mimics ghrelin and acts on GHS-R1a. Mod-GRF (1-29) mimics GHRH and acts on GHRHR. These are separate receptor systems with separate downstream pathways. In animal studies, combining a GHS compound with a GHRH analog has produced additive or synergistic GH release compared to either alone, which is the scientific basis for the pairing that vendors promote. The synergy data, however, comes largely from rodent studies and does not automatically translate to humans.

From a research-chemical quality standpoint, both peptides present the same verification challenges. Purity, accurate sequence, and correct molecular weight must be confirmed by certificate of analysis (COA) from an independent third-party lab. Vendors who do not publish COAs with mass spectrometry and HPLC data give buyers no way to confirm what they are actually receiving. This is a practical concern that applies equally to both compounds.

The evidence gap between animal pharmacology and human clinical outcomes is wider for these two peptides than vendor marketing typically acknowledges. GH pulse amplitude increasing in a rat model is a measurable, reproducible finding. Whether that translates to meaningful changes in body composition, recovery, or other endpoints in healthy adult humans over weeks or months is a separate question that the current published literature does not answer for either compound.